RT Journal Article
SR Electronic
T1 Investigation and analysis of the clinical application of Perampanel in the Southeast of China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.04.23288128
DO 10.1101/2023.04.04.23288128
A1 Li, Lingqi
A1 Huang, Yan
A1 Ma, Lei
A1 Shao, Zhiyu
YR 2023
UL http://medrxiv.org/content/early/2023/04/05/2023.04.04.23288128.abstract
AB Objective The aim of this study was to investigate the clinical trials of Perampanel (PER) at the First Affiliated Hospital of Xiamen University (FAHXU). Recommendations have been developed for the use of Perampanel in clinical practice.Design A retrospective single-center validation study.Setting A tertiary general hospital in Xiamen, a city located on the southeastern coast of China.Participants A total of 831 prescriptions were included for 188 patients were treated with Perampanel.Outcome measures Record the patient’s medication, including the diagnosis of the patient’s disease, the dose, course of medication, and the combination of medication, analyze the characteristics of the drug population and the medication unreasonableness by comparing the drug instructions and referring to relevant literature and guidelines.Results PER was mainly used in Neurology. Epilepsy is the most common conditions prescribed. There were 119 cases of inconsistent drug indications, 56 inappropriate dosing frequency, 3 inconsistent dose, and 6 inconsistent dose adjustment intervals.Conclusion There is an improper use of PER within the FAHXU. Greater attention should be paid to changes in patients’ condition and observation of discomfort following medication administration. Monitoring of PER use should be further enhanced. A rational drug evaluation system should be established to promote the rational use of PER.Article Summary Our study was one of the few studies on the clinical use of Perampanel, especially in Southeast China.As a third-generation antiepileptic drug, data on the clinical rational drug use of Perampanel is limited in China.There were several limitations worth noting. Firstly, the data in our study were collected at only one institution, thus not covering a broader population from other regions. Clinical outcomes, including medication efficacy and adverse events, were not tracked in patients with irrational medication use.Strengths and limitations Our study was one of the few studies on the clinical use of Perampanel, especially in Southeast China. As a third-generation antiepileptic drug, data on the clinical rational drug use of Perampanel is limited in China.There were several limitations worth noting. Firstly, the data in our study were collected at only two institutions, thus not covering a broader population from other regions. Clinical outcomes, including medication efficacy and adverse events, were not tracked in patients with irrational medication use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves human participants and was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.AEDantiepileptic drugALalprazolamBotox ABotulinum toxin ACBZCarbamazepineCSCorticosteroidsCZPClonazepamDPdiazepamFAfolic acidLEVLevetiracetamLEXAPROLexapro (Escitalopram)LTGlamotrigineOMPOmeprazoleOXCoxcarbazepinePBphenobarbitalPHBPhenobarbitalPTAPrednisone acetatePPCPolyene phosphatidylcholinePOT CLpotassium chlorideSVsodium valproateTPMtopiramateZBTzolpidem